LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
XENE
Xenon Pharmaceuticals Inc.
There isn't enough reported data to score XENE yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XENE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
XENE's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XENE PE Valuation
XENE has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
XENE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect XENE's revenue to grow, with its earnings and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over XENE on earnings quality, reporting a profit while its opponent remains loss making.
XENE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.70 | -$0.82 |
| Q2 2026 | -$4.74 | -$1.20 |
| Q1 2026 | -$4.70 | -$1.48 |
| Q4 2025 | -$4.36 | -$1.35 |
| Q3 2025 | -$3.88 | -$1.05 |
| Q2 2025 | -$3.54 | -$0.79 |
| Q1 2025 | -$3.22 | -$0.50 |
| Q4 2024 | -$3.01 | -$0.28 |
XENE lost $4.70 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over XENE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
XENE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $132K | -98% |
| Q2 2022 | $536K | -76% |
| Q1 2022 | $8.8M | +101% |
| Q4 2021 | $3.7M | -27% |
| Q3 2021 | $8.1M | +24% |
| Q2 2021 | $2.2M | -83% |
| Q1 2021 | $4.4M | -38% |
| Q4 2020 | $5.2M | +55% |
XENE's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -970% | N/A |
| Q3 2022 | -28885% | -28693 points |
| Q2 2022 | -5656% | -4641 points |
| Q1 2022 | -198% | +170 points |
| Q4 2021 | -665% | -414 points |
| Q3 2021 | -192% | -44 points |
| Q2 2021 | -1014% | -1010 points |
| Q1 2021 | -368% | -255 points |
XENE's operating margin was −970% last quarter, down 305 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over XENE on cash generation, producing positive trailing cash flow while its opponent burns cash.
XENE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$90.6M | -$18.6M |
| Q2 2026 | -$95.7M | -$31.3M |
| Q1 2026 | -$89M | -$27.3M |
| Q4 2025 | -$81.8M | -$26.6M |
| Q3 2025 | -$72M | -$20.3M |
| Q2 2025 | -$64.4M | -$30.2M |
| Q1 2025 | -$61.7M | -$18.3M |
| Q4 2024 | -$55.2M | -$19.6M |
XENE has burned cash in almost every quarter: −$357M over the past year, against −$253M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XENE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XENE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +156K shares |
| 1 year | +26% | +20.5M shares |
| 3 years | +51% | +33.8M shares |
| 5 years | +142% | +58.6M shares |
| Available history | +201% | +66.6M shares |
XENE has 100M diluted shares, up 26% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
XENE Net Leverage
XENE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XENE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 17.7 | Oversold |
XENE's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XENE PE vs Healthcare Sector
XENE has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over XENE on trend strength, trading above more of its moving averages.
XENE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.2 | 10% above |
| 20 week MA | $51.4 | 20% below |
| 50 week MA | $50.3 | 18% below |
| 100 week MA | $43.4 | 5.4% below |
| 200 week MA | $41.5 | 1.3% below |
XENE has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 1.3% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over XENE on returns for 2026, with the stronger performance.
XENE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.4 | $15.3 | +14% |
| 2021 | $15.3 | $30.5 | +100% |
| 2022 | $30.5 | $38.1 | +25% |
| 2023 | $38.1 | $46.1 | +21% |
| 2024 | $46.1 | $38.8 | -16% |
| 2025 | $38.8 | $44.8 | +15% |
| 2026 YTD | $44.8 | $41.0 | -8.6% |
XENE has finished higher in five of the last six years. It's down 8.6% so far in 2026.